Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Arrowhead Pharmaceuticals Inc Market Cap
Based on ratings from 15 stock analysts, the Arrowhead Pharmaceuticals Inc stock price is expected to increase by 99.72% in 12 months. This is calculated by using the average 12-month stock price forecast for Arrowhead Pharmaceuticals Inc. The lowest target is $23 and the highest is $80. Please note analyst price targets are not guaranteed and could be missed completely.
Arrowhead Pharmaceuticals Inc has a total of 15 Wall St Analyst ratings. There are 10 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Arrowhead Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ARWR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $80 | Maintains | Dec 3, 2024 |
| William Pickering Bernstein | Market Perform | $24 | Maintains | Nov 29, 2024 |
| Shawn Egan Citigroup | Neutral | $26 | Maintains | Nov 27, 2024 |
| Keay Nakae Chardan Capital | Buy | $60 | Maintains | Nov 27, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $45 | Maintains | Nov 27, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Nov 20, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Oct 11, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $62 | Reiterates | Oct 8, 2024 |
| Luca Issi RBC Capital | Outperform | $42 | Reiterates | Sep 26, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Sep 5, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Sep 3, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $55 | Reiterates | Aug 12, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Jul 23, 2024 |
| Keay Nakae Chardan Capital | Buy | $60 | Maintains | Jul 17, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Maintains | Jul 5, 2024 |
| Keay Nakae Chardan Capital | Buy | $60 | Maintains | Jun 26, 2024 |
| Alethia Young Cantor Fitzgerald | Overweight | Reiterates | Jun 20, 2024 | |
| Patrick Trucchio HC Wainwright & Co. | Buy | $90 | Reiterates | Jun 11, 2024 |
| Andrea Tan Goldman Sachs | Neutral | $31 | Initiates | Jun 5, 2024 |
When did it IPO
1997
Staff Count
525
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Christopher R. Anzalone Ph.D.
Market Cap
$2.94B
In 2023, ARWR generated $240.7M in revenue, which was a decrease of -1.03% from the previous year. This can be seen as a signal that ARWR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in the Piper Sandler Healthcare Conference and Evercore ISI HealthCONx Conference from December 3-5, 2024.
Why It Matters - Arrowhead Pharmaceuticals' participation in major healthcare conferences signals its ongoing engagement with investors and stakeholders, potentially impacting stock performance and investor sentiment.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Arrowhead Pharmaceuticals (NASDAQ: ARWR) has filed for regulatory clearance to start a Phase 1/2a trial for ARO-ALK7, an RNAi therapeutic aimed at treating obesity.
Why It Matters - Arrowhead Pharmaceuticals' initiation of a clinical trial for ARO-ALK7 could advance its position in the RNAi space, potentially driving stock value and attracting investor interest in obesity treatments.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - Arrowhead Pharmaceuticals shares surged 25% following a significant licensing agreement with Sarepta Therapeutics.
Why It Matters - Arrowhead Pharmaceuticals' stock surge reflects strong investor confidence due to the significant licensing deal, which could enhance revenue and growth prospects.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Arrowhead Pharmaceuticals will hold its Q4 2024 earnings conference call on November 26, 2024, at 4:30 PM ET, featuring key executives and analysts from major financial institutions.
Why It Matters - The earnings call provides insights into Arrowhead Pharmaceuticals' financial health and strategic direction, impacting valuation and investment decisions in the biotech sector.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its FY 2024 financial results, hosting a conference call on November 26, 2024, to discuss advancements in its TRiM™ technology for new medicines.
Why It Matters - Arrowhead Pharmaceuticals' financial results and potential drug advancements signal growth opportunities, influencing stock performance and investor sentiment in the biotech sector.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Sarepta Therapeutics has entered an exclusive global licensing agreement with Arrowhead Pharmaceuticals for multiple programs targeting rare genetic diseases affecting muscles, CNS, and lungs.
Why It Matters - Sarepta's collaboration with Arrowhead expands its pipeline in rare genetic diseases, potentially enhancing growth prospects and market position, influencing investor sentiment and stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
